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Dear Editor:
The liver is a common site for the development of metastases
in colorectal cancer. Since spread from the primary cancer site
is believed to happen via the portal vein, attempts have been
made to apply chemotherapy via this route in the immediate
postoperative period in order to eliminate micrometastases in
the liver. Following encouraging reports by others, the Swiss
Group for Clinical Cancer Research (SAKK) has performed a
large trial (SAKK 40/81) comparing perioperative intraportal
adjuvant chemotherapy with 5-fluorouracil (5-FU) and
mitomycin C with surgery alone (Swiss Group for Clinical
Cancer Research, Lancet 1995).
In this randomized multicenter trial, there was a sig-
nificant survival advantage following perioperative intra-
portal chemotherapy. In 1987, prior to the analysis of
SAKK 40/81, the SAKK initiated a subsequent randomized
three-arm trial (SAKK 40/87) which compared among
perioperative intraportal chemotherapy, the same intrave-
nous chemotherapy and surgery alone. In 1993, after a
significant survival benefit had been shown by the use of
adjuvant 5-FU in combination with levamisol (Moertel et
al., N Engl J Med 1990), the SAKK initiated a new three-
arm trial (SAKK 40/93), where all patients received
perioperative intraportal or intravenous chemotherapy and
were then randomised to additionally receive no further
treatment (arm A) or 5-FU 450 mg/m2 iv bolus weekly for
12 months in combination with levamisol (arm B) or 5-FU
600 mg/m2 iv bolus for 12 months (arm C). Due to the fact
that the previously reported adjuvant treatments with 5-FU
and levamisol had been restricted to colon cancer and
adjuvant radiochemotherapy by then had been established
in rectal cancer, in SAKK 40/93, only colon cancer patients
have been included. After 3.5 years and the inclusion of
284 patients, the trial had to be closed because the first
results of SAKK 40/87 became available that failed to
confirm an advantage of perioperative intraportal chemo-
therapy over surgery only (Laffer et al., Int J Colorectal Dis
epub August 8, 2008). In this letter, we would like to
report the results of this prematurely terminated trial,
SAKK 40/93.
Between September 1993 and May 1997, 284 [one
withdrew consent for his data, so only 283 patients were
evaluable] out of 1,500 planed patients have been random-
ized from 24 institutions in Switzerland, Germany, and
Luxembourg. Patient eligibility criteria included stages II
(pT 3/4, N0, M0) and III (any pT, pN+, M0), potentially
curative resection, no previous radio- or chemotherapy,
normal organ function, and absence of severe concomitant
disease.
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All analyses have been performed on an intention-to-
treat basis. In addition, for German-speaking patients, a
quality-of-life subtrial has been performed, the results of
which have been published elsewhere (Bernhard et al. Ann
Oncol 1999.).
Patient characteristics
Fifty-eight percent were male, 56% were <65 years of age,
median age was 63 years, 54% stage II, 83% received
intravenous perioperative chemotherapy.
Mostly, minor complications due to perioperative che-
motherapy have been observed in 13% (intraportal) and 9%
(intravenous), respectively.
Of 188 patients randomized to adjuvant chemotherapy,
21 never received any, mostly due to patient refusal. In a
further ten patients, documentation of chemotherapy was
not available. This left 80 patients in arm B and 77 patients
in arm C evaluable for chemotherapy. In arm B (5-FU
450 mg/m2), 94% of those who started chemotherapy
completed 6 months and 65% completed 12 months. In arm
C (5-FU 600 mg/m2), 75% completed 6 months and 51%
completed 12 months. In arm B >80% of the planed overall
dose of 5-FU could be administered to 67% of treatment
periods (12 weeks each), in contrast to only 50% in arm C.
Grade 3 or 4 non-hematologic toxicities have been
observed in 9% of patients on arm B and in 12% on arm C,
mostly diarrhea, during the first 12 weeks of the study.
Hematologic toxicity was rare and there were no differ-
ences between these two arms.
The primary endpoint of this trial was disease-free sur-
vival. At 5 years, the event-free survival rates were 64%,
68%, and 68% for treatment arm A, B, and C with no
statistical difference. Also, overall survival was not differ-
ent between treatment arms.
Exploratory multivariate Cox regression analyses con-
firmed male sex, N+ stage, T4, and age >65 years as
unfavorable prognostic indicators both for DFS and OS.
While treatment on arm C as compared to arm A was
associated with a significant DFS advantage (HR 0.279,
p=0.032).
In conclusion, this initially slowly accruing trial had to
be closed early for ethical reasons after new evidence had
emerged from the earlier trial. The patient numbers
available for analysis are far too small to draw any reliable
conclusion. However, one of the research questions,
namely, whether dose intensity is important in the adjuvant
treatment of colon cancer remains still open. This trial
demonstrates that higher bolus doses of 5-FU can be given
in the adjuvant setting without major toxicities, although
many patients had to have their doses reduced as time went
by. The finding that patients in arm C appeared to fare
better and the fact that women who are known to have a
lower tolerance to 5-FU do better overall, would support
more research of this issue.
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